0000950170-23-072374.txt : 20231221
0000950170-23-072374.hdr.sgml : 20231221
20231221201831
ACCESSION NUMBER: 0000950170-23-072374
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231219
FILED AS OF DATE: 20231221
DATE AS OF CHANGE: 20231221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Renaud Ronald C JR
CENTRAL INDEX KEY: 0001354434
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 231506922
MAIL ADDRESS:
STREET 1: C/O IDENIX PHARMACEUTICALS, INC.
STREET 2: 60 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2023-12-19
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001354434
Renaud Ronald C JR
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
true
true
false
false
President & CEO
false
Common Stock
2023-12-19
4
M
false
160452
A
160452
D
Common Stock
83857
I
By Trust
Restricted Stock Units
2023-12-19
4
M
false
160452
0.00
D
Common Stock
160452
0
D
In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.
Each RSU represented the contingent right to receive one share of the Issuer's common stock.
Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
/s/ Mark Bodenrader, as Attorney-in-Fact
2023-12-21